UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/17.12.25 | Market Closed - Börse Stuttgart 02:23:39 2024-07-08 am EDT | ||
| 1.61 EUR | -5.29% |
|
| Current month | -2.86% | ||
| 1 month | -23.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-08 | 1.61 | -5.29% |
| 24-07-05 | 1.7 | +6.25% |
| 24-07-04 | 1.6 | -0.62% |
| 24-07-03 | 1.61 | -8.00% |
| 24-07-02 | 1.75 | +2.34% |
Delayed Quote Börse Stuttgart
Last update July 08, 2024 at 02:23 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1H5A |
| ISIN | DE000HD1H5A4 |
| Date issued | 2023-12-28 |
| Strike | 700 $ |
| Maturity | 2025-12-17 (528 Days) |
| Parity | 10 : 1 |
| Emission price | 1.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.52 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.19 € |
| Spread % | 10.56% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
